2021’s

• Apr

  Completed Series B bridge funding
  

  Mar

  MoU signed with KangWon National University School of Medicine for collaborative research in the field of pulmonary fibrosis treatment

  Feb

  Registered "US Patent" for New Drug Candidate for Liver Fibrosis

2020’s

• May

  MoU signed with Chonnam National University Hospital

  Apr

  Strategic partnership with Nanion Technologies to open reference lab in Korea for CardioExcyte96 FLEXcyte96

2019’s

• Aug

  Completed Series B funding

  Aug

  Distribution agreement signed with KAC in the Japan for hiPSC-derived cell products

  May

  Novartis drug development team(VP level) visits NEXEL HQ

  Mar

  Distribution agreement signed with Cambridge Bioscience in the U.K. and Ireland for hiPSC-derived cell products

2018’s

• Jun

  Innobiz Certification

  May

  Commercial license (non-exclusive) for hiPSC-derived cell products obtained from iPS Academia Japan

  Mar

  ISO9001 certification

2017’s

• Dec

  Completed Series A funding
  

  Sep

  Invited to Novo Nordisk global collaboration business (with KOTRA)

  Aug

  MoU signed with T&R Biofab for the development of bioprinting technology using stem-cell derived cells

  May

  Distribution agreement with BOYA Medical for the distribution of iPSC-derived cell products

  Jan

  Domestic launch of cell products

2016’s

• Dec

  Tech. transfer of 6 patents from Korea University Industry-Academic Cooperation Foundation

  Nov

  License-in of cardiomyocyte differentiation technology from KIT

  Sep

  MoU signed for the development of toxicology platfoms using stem-cell derived cells with Korea Institute of Toxicology (KIT)

  Mar

  Corporate affiliated research institute certified
  

  Feb

  Venture company certified

2015’s

• May

  Name changed to NEXEL Co., Ltd.

2014’s

• Nov

  Picked as family company to Korea University Life Sciences College

  Sep

  MoU signed with IMPLAD China

2013’s

• Mar

  MoU signed with Korea University

2012’s

• Sep

  Founding of NEXCELL Bio